USPTO Examiner MCMILLIAN KARA RENITA - Art Unit 1623

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18948449USE OF ERGOTHIONEINE TO SUPPRESS DELETERIOUS EFFECTS OF SENESCENCENovember 2024January 2026Abandon1420YesNo
18908587COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAMEOctober 2024July 2025Allow920YesNo
18907258S-BETA-HYDROXYBUTYRIC ACID COMPOSITIONS AND METHODS FOR DELIVERY OF KETONE BODIESOctober 2024September 2025Allow1220NoNo
18888371SOLID PSILOCIN SALTSSeptember 2024April 2025Allow711NoNo
18796446Methods for Preventing Ectopic Brain Mineralization in Alzheimer's Disease and DementiasAugust 2024November 2025Abandon1621NoNo
18663460INHIBITING MONOACYLGLYCEROL LIPASE (MAGL)May 2024November 2024Allow610NoNo
186014455-BROMO-2-HYDROXY-N'-[(1E)-1-(PYRIDIN-2-YL) ETHYLIDENE]BENZOHYDRAZIDE AS AN ANTI-CANCER AND ANTIMICROBIAL AGENTMarch 2024May 2025Abandon1420NoNo
18594323TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORSMarch 2024April 2025Abandon1310NoNo
18594233METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORSMarch 2024October 2025Abandon1920NoNo
18431308POTENTIATION OF HELMINTH TREATMENTFebruary 2024April 2025Abandon1410NoNo
18406539TOPICAL FORMULATIONS OF CHLOROPROCAINE AND METHODS OF USING SAMEJanuary 2024September 2025Abandon2020YesNo
18403360STERICALLY STABILIZED CARRIER COMPOSITIONS FOR TREATING A MAMMALJanuary 2024November 2024Allow1101NoNo
184025386-[4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024October 2024Allow1030NoNo
183984804-[4,4-BIS(4-BROMOPHENYL)-5-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDDecember 2023October 2024Allow1030NoNo
18515734TREATING PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHYNovember 2023October 2024Allow1110NoNo
18495012NICOTINE FORMULATIONOctober 2023November 2024Abandon1310NoNo
18481787COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITYOctober 2023November 2024Abandon1310NoNo
18376339INJECTABLE IBUPROFEN FORMULATIONOctober 2023May 2025Abandon2020NoNo
18474108IMMUNOREGULATORY MICROPARTICLES FOR MODULATING INFLAMMATORY ARTHRITIDESSeptember 2023September 2024Allow1220YesNo
18457567METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORSAugust 2023November 2024Allow1510NoNo
18364796THERAPY OF POST-OPERATIVE EMESIS WITH AMISULPRIDEAugust 2023September 2025Abandon2630NoNo
18362028CCR2 RECEPTOR ANTAGONISTS AND USES THEREOFJuly 2023September 2024Allow1310NoNo
18223177DEUTERATED DERIVATIVES OF PSILOCYBIN AND USES THEREOFJuly 2023August 2025Abandon2520NoNo
18349221ACETYL-LEUCINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR IMPROVED MOBILITY AND COGNITIVE FUNCTIONJuly 2023April 2025Allow2130NoNo
18325919ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISMay 2023August 2024Allow1420NoNo
18141170TREPROSTINIL PRODRUGSApril 2023November 2025Abandon3120NoYes
18305589PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIAApril 2023September 2025Abandon2920NoNo
18302713PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAMEApril 2023December 2024Abandon2020NoNo
18181228PREVENTIVE TREATMENT OF MIGRAINEMarch 2023January 2026Abandon3510NoNo
18095877COMBINATION THERAPY WITH AN ANTITUMOR ALKALOIDJanuary 2023February 2025Abandon2520YesNo
18093774AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOFJanuary 2023October 2024Allow2120YesNo
18063486SYNERGISTIC EFFECTS, AUGMENTING ANTIMICROBAL EFFECTS OF LIPIDSDecember 2022January 2026Abandon3840NoNo
18059806SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOFNovember 2022July 2024Allow2020NoNo
17989298COLLAGEN-BASED DEVICE HAVING ANTIFUNGAL PROPERTIESNovember 2022March 2025Abandon2820NoYes
18049508ANTI-VIRAL AGENTS AND METHODS FOR ADMINISTRATION THEREOFOctober 2022March 2025Allow2940YesNo
17950802METHODS OF TREATING OCULAR INFLAMMATORY DISEASESSeptember 2022November 2024Allow2630YesNo
17849803LIQUID COMPOSITIONS COMPRISING TERPENES AND CANNABINOIDSJune 2022January 2026Abandon4301NoNo
17780936PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING FIBROSIS, COMPRISING PHEOPHORBIDE COMPOUND AS ACTIVE INGREDIENTMay 2022November 2025Abandon4210NoNo
17779730PROPHYLACTIC OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS IN HUMANSMay 2022October 2025Abandon4110NoNo
17745126GPR40 AGONISTSMay 2022December 2024Allow3151NoNo
17774051INHIBITOR OF BINDING BETWEEN PODOCIN AND KERATIN 8 FOR USE IN THE TREATMENT OF NEPHROTIC SYNDROMEMay 2022March 2026Abandon4610NoNo
17755084Schizophrenic Disorder Treatment using Combination TherapyApril 2022September 2025Allow4110NoNo
17768130Combination Therapy for Treating a Hematological MalignancyApril 2022October 2025Abandon4201NoNo
17768113Improved Topical Composition of ColchicineApril 2022September 2025Abandon4210NoNo
17713384Osteogenic agents and uses thereofApril 2022April 2025Allow3631NoNo
17766081PHARMACOLOGICAL COMPOSITION FOR TREATING PROCTOLOGICAL DISEASES (VARIANTS)April 2022December 2025Abandon4520NoNo
17763597PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA, CONTAINING UNNATURAL AMINO ACIDMarch 2022December 2025Abandon4411NoNo
17762666TREATMENT COMPRISING THE USE OF FXR AGONISTSMarch 2022September 2025Abandon4210NoNo
17683197Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory InfectionsFebruary 2022August 2024Allow3020NoNo
17579271NEXT GENERATION REMDESIVIR ANTIVIRALSJanuary 2022June 2025Allow4141NoNo
17624629IMIDAZOTHIAZOLE COMPOUNDS AND METHODS FOR TREATING PLANT NEMATODE INFECTIONSJanuary 2022November 2025Abandon4721NoNo
17608950EZH2 INHIBITOR AND USE THEREOFNovember 2021October 2025Allow4711YesNo
17513383PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOFOctober 2021February 2023Abandon1640NoYes
17605828DIMERIC OR POLYMERIC FORM OF MUTANT IDH INHIBITOROctober 2021April 2025Abandon4101NoNo
17605456DIHYDROPYRIMIDINE COMPOUND AND APPLICATION THEREOF AS DRUGOctober 2021February 2026Abandon5220NoNo
17603386PRODRUG OF CASPASE INHIBITOROctober 2021September 2025Abandon4720NoNo
17602910STABILIZATION OF SUSPENSION CONCENTRATES BY HIGHLY SULFONATED LIGNOSULFONATEOctober 2021February 2026Abandon5220NoNo
17602028BENZIMIDAZOLE DERIVATIVES AND THEIR USESOctober 2021August 2025Allow4620YesNo
17600194COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)September 2021July 2025Abandon4511NoNo
17600172COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)September 2021October 2025Abandon4820NoNo
17593877HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORSSeptember 2021January 2025Abandon4001NoNo
17598500METHOD OF PROTECTING FIELD CORN FROM DAMAGE BY A PLANT PATHOGENSeptember 2021January 2025Abandon4010NoNo
17441222PHARMACEUTICAL COMPOSITION FOR TREATING MACULAR DEGENERATION INCLUDING IMIDAZOLINE DERIVATIVE COMPOUND AS ACTIVE INGREDIENTSeptember 2021August 2025Abandon4720NoNo
17438841SPECIFICALLY SUBSTITUTED 3-(2-HALOGEN-6-ALKYL-4-PROPINYLPHENYL)-3-PYRROLIN-2-ONES AND TO THE USE THEREOF AS HERBICIDESSeptember 2021February 2025Abandon4101NoNo
17438452COMBINATION DRUG TREATMENT FOR HUMAN CYTOMEGALOVIRUSSeptember 2021January 2025Abandon4010NoNo
17437236INHIBITION OF ADENOVIRUS WITH FILOCICLOVIRSeptember 2021April 2025Allow4330NoNo
17406035CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONSAugust 2021March 2024Abandon3121NoNo
17431470MULTIPHASIC CONTRACEPTIVE AND/OR HORMONE REPLACEMENT THERAPYAugust 2021May 2025Abandon4411NoNo
17431460INHIBITOR OF BTK AND MUTANTS THEREOFAugust 2021January 2026Allow5321YesNo
17397984ARYL SULFIDE COMPRISING BENZYLAMINE, SYNTHESIS METHOD AND APPLICATION THEREOFAugust 2021July 2025Allow4821NoNo
17428029TREATMENT AND PREVENTION OF INTESTINAL INFLAMMATORY DISEASES WITH A BILE ACID DERIVATIVEAugust 2021January 2025Abandon4110NoNo
17426805NOVEL DEVICESJuly 2021March 2026Abandon5621NoYes
17381857COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATIONJuly 2021June 2024Abandon3531NoNo
174196646-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOFJune 2021February 2025Abandon4301NoNo
17309764HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDSJune 2021August 2025Allow5021NoNo
17331366METHODS OF TREATING THROMBOSISMay 2021March 2025Allow4541YesNo
17331599ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONMay 2021November 2025Abandon5421NoNo
17289816TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINEApril 2021May 2025Abandon4941NoNo
17258724USE OF COMPOUND IN DRUG FOR PREVENTING, TREATING, OR ALLEVIATING PAINJanuary 2021November 2025Abandon5951NoNo
17099531ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISNovember 2020November 2024Abandon4840YesNo
17052192NOVEL HETEROCYCLE DERIVATIVENovember 2020October 2025Allow5931NoNo
17014954CANNABINOID FORMULATIONS AND METHODS INCLUDING THE ANTIOXIDANT C60September 2020November 2024Abandon5040NoNo
16767886COMPOSITIONS AND METHODS FOR CHARACTERIZING CANCERMay 2020November 2024Abandon5440YesNo
16624549Stratification Of Acute Myeloid Leukaemia Patients For Sensitivity To Kinase Pathway Inhibitor TherapyDecember 2019December 2024Allow6041YesNo
16419927Method for activating AMPK and the use of AdenineMay 2019August 2025Abandon6080YesYes
16419892Method for activating AMPK and the use of AdenineMay 2019May 2025Abandon6040YesYes
16277871COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSISFebruary 2019February 2020Allow1210NoNo
16309733PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF PAINDecember 2018January 2025Abandon6040YesYes
16065441COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIAJune 2018September 2024Allow6070YesYes
15732352Method for producing solid formulations with improved dissolution by annealing with an adjuvantOctober 2017September 2021Abandon4761NoNo
15727772COMPOSITIONS FOR TOPICAL TREATMENT OF MICROBIAL INFECTIONSOctober 2017September 2024Allow60100YesNo
15062499ORAL AND INJECTABLE FORMULATIONS OF TETRACYCLINE COMPOUNDSMarch 2016March 2025Abandon6060YesYes
14883720INHIBITORS OF BETA-SECRETASEOctober 2015November 2018Allow3721YesNo
14792375Na/K-ATPase Ligand and Uses Thereof in Wound HealingJuly 2015September 2016Allow1410YesNo
14734999COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASESJune 2015May 2018Allow3530YesYes
14342889PHARMACEUTICAL AGENT FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS OR SUPPRESSING DISEASE PROGRESS THEREOFMarch 2014June 2020Abandon6080YesYes
140103542-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological DisordersAugust 2013May 2015Allow2110NoNo
13965499PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISMAugust 2013June 2015Allow2230YesNo
13942245PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISMJuly 2013June 2015Allow2330YesNo
13986573Method for treament of neurologic dysfunctionMay 2013February 2016Allow6020NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCMILLIAN, KARA RENITA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
10
(83.3%)
Examiner Reversed
2
(16.7%)
Reversal Percentile
27.5%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
28
Allowed After Appeal Filing
8
(28.6%)
Not Allowed After Appeal Filing
20
(71.4%)
Filing Benefit Percentile
41.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCMILLIAN, KARA RENITA - Prosecution Strategy Guide

Executive Summary

Examiner MCMILLIAN, KARA RENITA works in Art Unit 1623 and has examined 93 patent applications in our dataset. With an allowance rate of 67.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner MCMILLIAN, KARA RENITA's allowance rate of 67.7% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MCMILLIAN, KARA RENITA receive 2.81 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCMILLIAN, KARA RENITA is 47 months. This places the examiner in the 8% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +42.6% benefit to allowance rate for applications examined by MCMILLIAN, KARA RENITA. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.5% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 27% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 38.0% are granted (fully or in part). This grant rate is in the 26% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.3% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.